Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation; Sanofi

    • Most Recent Events

    • 13 Sep 2020 Results (n=1216) of analysis assessing autoimmune adverse events from five clinical studies: NCT00050778, NCT00530348, NCT00548405, NCT00930553, NCT02255656 presented at the 8th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
    • 01 May 2020 Results assessing relapse rates before, during, and after the first pregnancy in alemtuzumab-treated RRMS patients over 8 years in in phase 2 and 3 core clinical trials (CAMMS223 [NCT00050778]; CARE-MS I [NCT00530348]; CARE-MS II [NCT00548405]), and their extension studies (CAMMS03409 [NCT00930553]; TOPAZ [NCT02255656]), presented at the 72nd Annual Meeting of the American Academy of Neurology
    • 28 Oct 2017 Results of analysis providing updated pregnancy outcomes in alemtuzumab-treated female patients from the clinical development program trials (NCT00050778, [NCT00530348, NCT00548405, NCT00930553, NCT02255656) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top